secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001739410-24-000012
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio cuts 45% of workforce, extends cash runway to mid-2026
---------------------------------------------------------------

- Workforce reduction of 45% (19 positions); expects ~$3.3M in severance charges.
- Preliminary cash, equivalents and marketable securities of $109.9M as of Dec 31, 2023.
- Prioritizes Phase 2-ready programs RLYB212 (FNAIT) and RLYB116 (C5 inhibitor).
- Cash runway extended into mid-2026; preclinical programs seek alternative funding.
- RLYB212 Phase 2 update with EMA expected H1 2024; Phase 2 initiation in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/0001739410-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/rlyb-20240206.htm
  HTML page:      https://secwatch.observer/filing/0001739410-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer